Abstract
Importance The coronavirus disease 2019 (Covid-19) pandemic continues to place a devastating strain on healthcare services worldwide and there remains an ongoing requirement for new treatments. A key mechanism recognised in progressive severe disease is virus-induced endothelial dysregulation. Endothelin-1 (ET-1), being the most highly expressed peptide in endothelial cells and potent vasoconstrictor of human blood vessels, represents a potential therapeutic target through the use of Endothelin receptor antagonists.
Objective To investigate the association of plasma ET-1 with Covid-19 disease severity
Design Retrospective longitudinal cohort study of Covid-19 patients divided into Group A (asymptomatic or symptoms not requiring hospitalisation), Group B (symptoms requiring hospitalisation) and Group C (symptoms requiring supplemental oxygen therapy or assisted ventilation) recruited between March and July 2020 (the first wave of the Covid-19 pandemic in the UK). Data were compared with a contemporaneous cross-section of non-infected volunteers (Controls).
Setting Single Tertiary National Health Service Hospital.
Participants Tissue banked plasma samples were obtained from 194 patients.
Exposures Quantitation of ET-1 in plasma by specific enzyme linked immunosorbent assay.
Main outcome and measures Pairwise comparison of ET-1 levels (median [IQR]) between patient categories, and subgroups defined by clinical outcomes.
Results Baseline ET-1 plasma levels (pg/ml) were elevated in patients requiring hospitalisation compared with controls and patients with asymptomatic or mild infection (Group B: 1.59 [1.13-1.98], and Group C: 1.65 [1.02-2.32] versus controls: 0.68 [0.47-0.87], p=<0.001 and Group A: 0.72 [0.57-1.10], p=<0.001). ET-1 levels were also elevated in patients that died (2.09 [1.66-3.15]), developed acute kidney (1.70 [1.07-2.36]) or myocardial injury (1.50 [0.92-2.28]) compared with patients with an uncomplicated infection (1.00 [0.61-1.57], p=<0.01). Amongst surviving hospitalised patients, ET-1 concentrations decreased when measured at 28 days (Group B: 0.86 [0.60-1.61] and Group C: 1.17 [0.66-1.62] versus baseline, p=<0.05) and 90 days (Group B: 0.69 [0.59-1.38] and Group C: 1.01 [0.64-1.21] versus baseline, p=<0.05).
Conclusions and relevance Hospitalised Covid-19 patients demonstrate elevated ET-1 levels during the acute phase of infection and this is associated with increasing clinical severity of the disease. The results support the hypothesis that endothelin receptor antagonists may be beneficial for certain Covid-19 patients.
Question What is the association of the endothelial peptide and potent vasoconstrictor: endothelin-1 with disease severity in Covid-19 infection?
Findings Hospitalised Covid-19 patients (especially those requiring supplemental oxygen and assisted ventilation, dying patients, and those who developed acute myocardial or kidney injury) have higher circulating endothelin-1 levels during the acute phase of their infection, compared with patients with asymptomatic or only mildly symptomatic Covid-19 infection.
Meaning Endothelial dysregulation is a well-recognised mechanism for progressive severe Covid-19 infection and these results suggest targeting endothelin-1 activity through the use of Endothelin receptor antagonists may be of benefit.
Competing Interest Statement
MA, PJG and PA are employees of AstraZeneca (UK) Plc. All other authors have no disclosures.
Funding Statement
The study was funded in full or part by The Jon Moulton Charity Trust (GRA, APD, SPH); National Institute of Health Research, Cambridge Biomedical Research Centre, BRC-1215-20014 (JC); Biomedical Resources Grant, University of Cambridge, Cardiovascular Theme RG64226 (GRA, REK, APD), British Heart Foundation, TG/18/4/33770, (APD, JJM). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was obtained from the East of England: Cambridge Central Research Ethics Committee ('NIHR Bioresource': REC:17/EE/0025)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵§ Joint senior authors.
Funding: Supported in full or part by The Jon Moulton Charity Trust (GRA, APD, SPH); National Institute of Health Research, Cambridge Biomedical Research Centre, BRC-1215-20014 (JC); Biomedical Resources Grant, University of Cambridge, Cardiovascular Theme RG64226 (GRA, REK, APD), British Heart Foundation, TG/18/4/33770, (APD, JJM). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.
Disclosures: MA, PJG and PA are employees of AstraZeneca (UK) Plc. All other authors have no disclosures.
Data Availability
All data that support the findings of this study are available from the corresponding author upon reasonable request
